Miller Lab

Dr. Tim Miller (@TimMillerNeuro @WashUNeurology) recently shared new Phase 3 #tofersen results at ENCALS 2022. Check out the full dataset here: alscenter.wustl.edu/new-12-month-t…

I am honored to be a part of @NIHprevents' next #PreventionInFocus webinar on October 10 at 2:00 p.m. ET, to discuss the promise of strategies to prevent Alzheimer’s disease. Register at prevention.nih.gov/education-trai…

We're breaking our posting silence to congratulate Miller Lab graduate student @MiweiHu on her excellent poster presentation at the @RCFNeuro Tau Consortium last week. Miwei discussed the effects of #tau splicing on #sleep in #tauopathy. Keep up the great work!

Cool work coming out of @adrianisaacslab from former Miller Lab graduate student @AlexCammack. Can’t wait to dive into the data!

Thank you @MtlSyndrome for your generous support! We look forward to working with you on this exciting project to develop a potential treatment for Mitchell Syndrome! neurology.wustl.edu/medical-advanc…

Huge congratulations to Dr. Miller on being elected to the National Academy of Medicine! We’re lucky to have you at the helm!

Congratulations, Alex! We look forward to seeing more of your exciting and important work!

.@TimMillerNeuro This Is Your Life! Happy to host a virtual reunion of Miller Lab alumni to celebrate the FDA approval of #tofersen for SOD1 #ALS. Congrats to Tim and everyone involved!

BREAKING: the FDA has approved a new drug called toferson for a rare form of ALS caused by mutations in the gene SOD1. #WashUMed researcher @MillerLabNeuro, MD, PhD, led the international clinical trials. @ALSCenterWashU @biogen medicine.wustl.edu/news/drug-for-…

New SOD1 #ALS drug candidate, #tofersen, is up for review by an FDA Advisory Committee on Wednesday, March 22nd from 9:15 am - 6 pm EST. You can watch the meeting virtually here: youtube.com/live/K0k6Jfcc5…

5. More studies and randomized controlled trials in humans will be needed to understand the potential neuroprotective benefit of #lovastatin to ALS patients.

4. #Lovastatin treatment in ALS model mice delayed the onset of motor impairments, prolonged survival, and preserved spinal motor neurons.

What if we could identify treatments for #ALS from the drugs people already take? 💊 That’s exactly what our latest collaborative work tested. Here are a few exciting takeaways from the full study, published in @ANA_journals: onlinelibrary.wiley.com/doi/10.1002/an…

Exciting news! Well deserved honor for @TimMillerNeuro and colleagues!

“They are exceptional change makers." Neuroscience majors Sam Norwitz and Ephraim Oyetunji of #WashU23 were finalists for the Rhodes Scholarship, one of the world’s most prestigious academic honors, to study at the University of Oxford in England. bit.ly/3trNygE

Read our latest paper out in @NatureComms on genotype-phenotype correlations in SOD1-#ALS. This is the largest study of its kind for #SOD1 variants. Great work led by @opie_martin and @AlfredoIacoange at @KingsCollegeLon ! nature.com/articles/s4146…

Delighted to share a major step forward in treating #ALS. Published results for ASO therapy #Tofersen for #SOD1 ALS medicine.wustl.edu/news/investiga… Tremendous thank you to the trial participants, their caregivers, and site personnel.